FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol  Sorrento Therapeutics Inc. [SPNE]							Relationship of Reporting Person(s) to Issuer     (Check all applicable)						
ABG Management Ltd											Director X 10% Owner				10% Owner		
,	•	(Middle)		09/12/2018						Officer (give title Other (spe below) below)			Other (specify below)				
		· · · · · · · · · · · · · · · · · · ·		4. If Amendment, Date of Original Filed (Month					Month/[	Day/Y	ear)	6. Individu	al or J	oint/Gro	up Filing	(Check Applicable	
GLOUCESTER TOWER, THE LANDMARK, CENTRAL													Line) Form filed by One Reporting Person				
(Street) HONG KONG K3 00000														ed by Mo	ore than	One Reporting	
(Sta	ite)	(Zip)															
	Ta	ble I - Non-D	eriva	ative	Secur	itie	s Acq	uire	d, Dispo	sed o	f, o	r Benefi	cially Ow	ned			
1. Title of Security (Instr. 3)		Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned		6. Ownership Form: Direct (D) or		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) or (D)	Р	rice	Reported Transaction		(Instr. 4)		
tock		09/12/2018	3				S		189,754	l D	\$	55.0597	1,120,8	34		I	Through ABG II- SO Limited <sup>(1)(2)(3)(4)(5)</sup>
tock		09/13/2018	3				S		29,137	D	\$	55.0059	1,091,6	97		[ ]	Through ABG II- SO Limited <sup>(1)(2)(3)(4)(5)</sup>
tock		09/13/2018	3				S		78,677	D	\$	4.9159	1,013,0	20		[ ]	Through ABG II- SO Limited <sup>(1)(2)(3)(4)(5)</sup>
tock													1,328,5	29		I	Through Ally Bridge LB Healthcare Master Fund Limited <sup>(1)(2)(3)(4)(6)</sup>
tock													3,041,7	59		[ ]	Through ABG SRNE Limited <sup>(1)(2)(3)(4)(7)</sup>
tock													1,408,0	27	1	[ ]	Through ABG Innovation-SO Limited <sup>(1)(2)(3)(4)(8)</sup>
													/ Owned				
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transa	5. Number o Derivative Securities Acquired (A or Disposed		er of e s I (A) sed nstr.	6. Date Exer Expiration I (Month/Day ed str.		ate Exercisable and ration Date nth/Day/Year)		sable and 7. Title and Amount of Securities Underlying		Derivative Security (Instr. 5) Bene Own Folic Repo		ative of the property of the p		(Instr. 4)
			Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title							
\$8.5							(9)		05/31/2019			432,432		43:	2,432	I	Through Ally Bridge LB Healthcare Master Fund Limited(1)(2)(3)(4)(6)
\$8.5							(9)		05/31/2019			432,432	:	43:	2,432	I	Through ABG SRNE Limited <sup>(1)(2)(3)(4)(7)</sup>
	(First 2-3004, 30 TER TOV	(First) 3-3004, 30TH FLOOR TER TOWER, THE LA  NG K3 (State)  Tal curity (Instr. 3)  Cock  Cock	(First) (Middle) -3004, 30TH FLOOR TER TOWER, THE LANDMARK,  NG K3 00000  (State) (Zip)  Table I - Non-D curity (Instr. 3) 2. Transaction Date (Month/Day/Yei  cock 09/13/2018 cock 09/13/2018 cock 09/13/2018 cock 3. Transaction Corresorios of Corresorios of Corresorios of Corresorios of Price of Derivative Security (Month/Day/Year)	(First) (Middle) (First	(First) (Middle)  (First) (Mid	Inagement Ltd  (First) (Middle)  3. Date of Equipment Ltd  3. Date of Equipment Ltd  4. If Amendment Amendment Ltd  (State) (Zip)  Table I - Non-Derivative Security (Instr. 3)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  Date (Month/Day/Year)  (Month/Day/Year)  Date (State) (Zip)  Table II - Derivative Security (e.g., puts, calls, with Cock  Derivative Security (e.g., puts, calls, with Code (Instr. Bransaction Date, if any (Month/Day/Year) (Month/Day/Year)  Derivative Security (e.g., puts, calls, with Code (Instr. Bransaction Date, if any (Month/Day/Year) (Month/Day/Year)  Security Security (e.g., puts, calls, with Code (Instr. Bransaction Date, if any (Month/Day/Year) (Month/Day/Year) (P.) (if any (Month	A sock  Table II - Derivative Securities (e.g., puts, calls, warr (Month/Day/Year) and price security  Table II - Derivative Securities (e.g., puts, calls, warr (Month/Day/Year) and price security  Table II - Derivative Securities (e.g., puts, calls, warr (Month/Day/Year) and price security  Table II - Derivative Securities (e.g., puts, calls, warr (Month/Day/Year) and price security  Table II - Derivative Securities (e.g., puts, calls, warr (Month/Day/Year) and price security (Month/Day/Year)	Sorrento Therapy   3. Date of Earliest Trans. 09/12/2018   4. If Amendment, Date of State)   Code (Instr. 3)   Sorrento Therapy   (Month/Day/Year)   (Month/Day/Year)   (Month/Day/Year)   Sorrento Therapy   (Month/Day/Year)   (Month/Day/Yea	Sorrento Therapeu   3. Date of Earliest Transaction   09/12/2018   4. If Amendment, Date of Originary   09/12/2018   5.	Code   Conversion   Conversio	Sorrento Therapeutics. Inc. [SR 3. Date of Earliest Transaction (Month/Day/Year 09/12/2018 4. If Amendment, Date of Original Filed (Month/Day/Year) 12/2018 4. If Amendment, Date of Original Filed (Month/Day/Year) 12/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 12/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It Amendment, Date of Original Filed (Month/Day/Year) 13/2018 5. It	Sorrento Therapeutics, Inc. [SRNE] 3. Date of Earliest Transaction (Month/Day/Year) 09/12/2018  4. If Amendment, Date of Original Filed (Month/Day/Year) 09/12/2018  Table I - Non-Derivative Securities Acquired, Disposed of, or Date (Month/Day/Year) 09/12/2018  Table II - Non-Derivative Securities Acquired Disposed Of (D) (Instr. 8)  Date (Month/Day/Year) 09/12/2018  S	Sometion   Sometion	Check all	Creeck all applies   Check all applies   Che	Sometic Therapeutics	Sometive   Sometive

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Security (Instr. or Exercise (Month/Day/Year)		3A. Deemed Execution Date, if any (Month/Day/Year)	n Date, if Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Warrants	\$8.5							(10)	06/07/2019	Common Stock	540,540		540,540	I	Through ABG SRNE Limited <sup>(1)</sup> (2)(3)(4)(7)

	Ψ8.5					
		Reporting Perso	on <sup>*</sup>			
ABG Ma	nagem	ent Ltd				_
(Last)	(	First)	(Middle)			
		TH FLOOR	NDMARK, CI	ENTD	ΛŢ	
———	TER TOV	VER, THE EA	TVDIVITAICIC, CI		TL	_
(Street) HONG KO	NG I	<b>Κ3</b>	00000			_
(City)	(	State)	(Zip)			
		Reporting Person	on <sup>*</sup>			
ABG II-S	O Ltd					
(Last)	(	First)	(Middle)			
UNIT 3002	-3004, 30	TH FLOOR				
GLOUCES	TER TOV	VER, THE LA	NDMARK, Cl	ENTRA	AL	
(Street)						
HONG KO	NG I	<b>Κ3</b>	00000			_
(City)	(	State)	(Zip)			
		Reporting Person	on <sup>*</sup>			
ABG Inn	<u>ovation</u>	<u>-SO Ltd</u>				
(Last)	(	First)	(Middle)			
UNIT 3002	-3004, 30	TH FLOOR				
GLOUCES	TER TOV	VER, THE LA	NDMARK, Cl	ENTRA	AL	
(Street)						
HONG KO	NG I	<b>Κ3</b>	00000			
(City)	(	State)	(Zip)			
1. Name and	Address of	Reporting Person	on <sup>*</sup>			_
ABG SR	NE Ltd					
(Last)	(	First)	(Middle)			

UNIT 3002-3004, 30TH FLOOR

K3

(State)

(Street) HONG KONG

(City)

GLOUCESTER TOWER, THE LANDMARK, CENTRAL

00000

(Zip)

(Loot)	(Eirot)	/M:dda)
(Last) UNIT 3002-3004	(First)	(Middle)
		NDMARK, CENTRAI
Street)		
HONG KONG	K3	00000
(City)	(State)	(Zip)
Name and Addres	ss of Reporting Pers	
	Group Innovat	
Partners III, L		•
(Last)	(First)	(Middle)
UNIT 3002-3004	, 30TH FLOOR	
GLOUCESTER 7	ΓOWER, THE LA	NDMARK, CENTRA
Street)		
HONG KONG	K3	00000
(City)	(State)	(Zip)
. Name and Addres	ss of Reporting Pers	on <sup>*</sup>
Ally Bridge L	B Healthcare	Master Fund Ltd
Last)	(First)	(Middle)
,	F, WHEELOCK H	
20 PEDDER STF	REET, CENTRAL	
Street)		
HONG KONG	K3	00000
(City)	(State)	(Zip)
. Name and Addres	ss of Reporting Pers	on <sup>*</sup>
Ally Bridge L	B Manageme	ent Ltd
(Last)	(First)	(Middle)
,	, WHEELOCK H	, ,
20 PEDDER STE	REET, CENTRAL	
Street)		
HONG KONG	K3	00000
(City)	(State)	(Zip)
None and Address	es of Panartina Da	
	ss of Reporting Pers	ווע
Li Bin		
Li Bin (Last)	(First)	(Middle)
Li Bin (Last) UNIT 1602, 16/F	(First) F, WHEELOCK H	OUSE
Li Bin (Last) UNIT 1602, 16/F 20 PEDDER STF	, WHEELOCK H	OUSE
Li Bin (Last) UNIT 1602, 16/F	, WHEELOCK H	OUSE
Li Bin (Last) UNIT 1602, 16/F 20 PEDDER STE	F, WHEELOCK HOREET, CENTRAL	OUSE

1. Name and Addres Yu Fan	ss of Reporting P	erson*
(Last)	(First)	(Middle)
UNIT 3002-3004	, 30TH FLOOI	?
GLOUCESTER T	TOWER, THE	LANDMARK, CENTRAL
(Street)		
HONG KONG	K3	00000
(City)	(State)	(Zip)

## **Explanation of Responses:**

- 1. The Reporting Persons are making this joint, single filing because they may be deemed to constitute a "group" within the meaning of Section 13(d)(3) of the Securities Exchange Act 1934 as amended (the "Act")
- 2. The Form 4 is filed by and on behalf of each of the following persons (each a "Reporting Person"): (i) ABG II-SO Limited ("ABG II-SO"), a British Virgin Islands limited company, (ii) Ally Bridge Group Capital Partners II, L.P., a Cayman Islands limited partnership, (iii) Ally Bridge LB Healthcare Master Fund Limited ("ABG LB"), a Cayman Islands limited company, (ii) Ally Bridge LB Management Limited, a Cayman Islands limited company, (vi) ABG SRNE Limited ("ABG SRNE"), a British Virgin Islands limited company, (vi) Ally Bridge Group Innovation Capital Partners III, L.P., a Cayman Islands limited company, (vii) ABG Management Ltd., a Cayman Islands limited partnership, (viii) ABG Innovation-SO Limited, a British Virgin Islands limited company,
- 3. (ix) Mr. Fan Yu, a director of ABG LB and a shareholder and director of Ally Bridge LB Management Limited, and the sole shareholder and director of ABG Management Ltd., and (x) Mr. Bin Li, a director and executive officer of ABG LB and a shareholder and director of Ally Bridge LB Management Limited.
- 4. Each Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for the purpose of Section 16 of the Act or otherwise, the beneficial owner of any securities covered by this statement. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
- 5. ABG II-SO directly owns 1,013,020 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Capital Partners II, L.P., as parent of ABG II-SO, (ii) ABG Management Ltd., as manager of Ally Bridge Group Capital Partners II, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
- 6. ABG LB directly owns (i) 1,328,529 shares of common stock of the Issuer and (ii) warrants to purchase 432,432 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge LB Management Limited, as manager of ABG LB, (ii) Mr. Fan Yu, as a shareholder and director of Ally Bridge LB Management Limited, and (iii) Mr. Bin Li, as a shareholder and director of Ally Bridge LB Management Limited.
- 7. ABG SRNE directly owns (i) 3,041,759 shares of common stock of the Issuer and (ii) warrants to purchase 972,972 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Innovation Capital Partners III, L.P., as owner of the sole voting share of ABG SRNE, (ii) ABG Management Ltd., as manager of Ally Bridge Group Innovation Capital Partners III, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
- 8. Ally Bridge Group Innovation Capital Partners III, L.P. is the owner of the sole voting share of ABG Innovation-SO Limited, which directly owns 1,408,027 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Innovation Capital Partners III, L.P., (ii) ABG Management Ltd., as manager of Ally Bridge Group Innovation Capital Partners III, L.P., and (iii) Mr. Fan Yu. as sole shareholder and director of ABG Management Ltd.
- 9. The warrants are exercisable at any time on or after May 31, 2016.
- 10. The warrants are exercisable at any time on or after June 7, 2016.

## Remarks:

By: /s/ Yu Fan on behalf of ABG Management Ltd.	09/14/2018
By: /s/ Yu Fan on behalf of ABG Management Ltd.	09/14/2018
By: /s/ Yu Fan on behalf of ABG Innovation-SO Limited	09/14/2018
By: /s/ Yu Fan on behalf of ABG SRNE Limited	09/14/2018
By: /s/ Yu Fan on behalf of Ally Bridge Group Capital Partners II, L.P.	09/14/2018
By: /s/ Yu Fan on behalf of Ally Bridge Group Innovation Capital Partners III, L.P.	09/14/2018
By: /s/ Yu Fan on behalf of Ally Bridge LB Healthcare Master Fund Limited	09/14/2018
By: /s/ Yu Fan on behalf of Ally Bridge LB Management Limited	09/14/2018
By: /s/ Yu Fan on behalf of Li Bin	09/14/2018
<u>/s/ Yu Fan</u>	09/14/2018
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.